Clinical Trial Update: Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial testing BIBF 1120 (nintedanib) added to low-dose cytarabine in elderly patients with Acute Myeloid Leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BIBF 1120 (nintedanib)
• Low-dose cytarabine (Cytarabine (low-dose))

Snippet

Sponsor: University Hospital Muenster | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: UNKNOWN